Is mifepristone (RU‑486) safe for use in patients with liver disease?

Can Mifepristone Be Given in Liver Disease?

Mifepristone should NOT be used in patients with severe hepatic disease, but can be used with caution and dose limitation (maximum 600 mg/day) in patients with mild-to-moderate hepatic impairment (Child-Pugh Class A-B). 1

Evidence-Based Recommendations by Severity of Liver Disease

Severe Hepatic Disease (Child-Pugh Class C or Decompensated Cirrhosis)

• Contraindicated - The FDA drug label explicitly states that mifepristone is not recommended in patients with severe hepatic disease, as pharmacokinetics have not been studied in this population 1
• No safety data exists for this patient group
• The drug is primarily metabolized by CYP3A4 in the liver, raising concerns about accumulation and toxicity 1

Mild-to-Moderate Hepatic Impairment (Child-Pugh Class A-B)

• Can be used with dose restriction: Maximum dose should not exceed 600 mg per day 1
• Pharmacokinetic studies in Child-Pugh Class B patients showed similar drug exposure compared to those with normal hepatic function, though with large variability 1
• The geometric mean ratio for AUC was 1.02 (95% CI: 0.59-1.76), indicating no significant difference, but the wide confidence interval reflects substantial individual variation 1
• Close monitoring is essential: Increased clinical and laboratory monitoring of liver function is required 2

Critical Safety Considerations

Known Hepatotoxicity Risk

Mifepristone has documented cases of drug-induced liver injury (DILI), particularly when used chronically at higher doses for Cushing syndrome:

• Case reports document severe cholestatic liver injury with jaundice, pruritus, and mixed hepatocellular/cholestatic patterns 3, 4
• One case showed focal endothelialitis in central venules, suggesting a vascular mechanism similar to anabolic steroid-induced liver injury 3
• Symptoms typically develop within 1-3 months of initiating therapy 3, 4
• Recovery occurs after drug discontinuation, but may take 1-4 months for complete resolution 3, 4

Pre-existing Liver Disease as a Risk Factor

• Animal studies demonstrate reversible hepatotoxicity with 30-day consecutive high-dose administration 5
• The structural similarity to anabolic steroids suggests potential for cholestatic injury and vascular complications 3

Practical Clinical Algorithm

Step 1: Assess Liver Disease Severity

• Obtain Child-Pugh score if cirrhosis is present
• Check baseline liver enzymes (AST, ALT, alkaline phosphatase, bilirubin)
• Assess for signs of decompensation (ascites, encephalopathy, variceal bleeding)

Step 2: Decision Making

• Child-Pugh C or decompensated: Do NOT prescribe mifepristone
• Child-Pugh B: Use only if benefits clearly outweigh risks; maximum 600 mg/day
• Child-Pugh A or compensated: Can use with maximum 600 mg/day
• No cirrhosis but chronic liver disease: Can use with maximum 600 mg/day and close monitoring

Step 3: Monitoring Protocol

• Baseline liver function tests before initiation
• Repeat liver enzymes at 2 weeks, 1 month, then monthly for first 3 months
• Instruct patient to immediately report jaundice, dark urine, severe pruritus, or right upper quadrant pain
• Discontinue immediately if ALT/AST >3x upper limit of normal or any elevation with symptoms

Important Caveats

Drug Interactions

Mifepristone is both a substrate and inhibitor/inducer of CYP3A4, creating significant potential for drug interactions that could further stress hepatic function 1. Avoid concurrent use of other hepatotoxic medications.

Contraceptive Context

For single-dose or short-course use (medical abortion with 200-600 mg), the hepatotoxicity risk is substantially lower than chronic high-dose use for Cushing syndrome. The documented DILI cases occurred with chronic administration 3, 4. However, even single-dose use should be avoided in severe hepatic disease per FDA labeling 1.

Paradoxical Benefit in Cushing Syndrome

Interestingly, case reports show that mifepristone treatment of hypercortisolism-associated fatty liver disease can improve liver enzymes and resolve hepatic steatosis 6, 7. This reflects treatment of the underlying cortisol excess rather than direct hepatoprotection, and does not negate the intrinsic hepatotoxicity risk of the drug itself.